Kornimate/medical-research-clean huggingface dataset:
automated video-assisted smoking treatment for people living with hiv

Conditions: Smoking Cessation

Summary: this study will evaluate if automated treatment performs better, in terms of facilitating long-term smoking abstinence, than the more resource-intensive standard treatment.


Eligibility criteria:
inclusion criteria: * smoked \>/=100 cigarettes in lifetime * english or spanish speaking * currently smoke \> 5 cigarettes/day * willing to make a quit attempt within 1 week of enrollment * hiv positive * process a smartphone compatible with the project app * have a valid email address exclusion criteria: * currently pregnant or breastfeeding * current use of smoking cessation medications * enrolled in a smoking cessation study * household member enrolled in the study * failure to electronically confirm participation within 14 days of randomization via electronic link sent to participant's smartphone
hiv-dna dynamics in hiv monoinfected or hiv/hcv coinfected patients

Conditions: HIV

Summary: new markers of viral activity are now under investigation. aim of the study is to investigate the efficacy of new antiretroviral drugs by monitoring hiv-dna dynamics in hiv-positive population. in hiv/hcv coinfected population, the study of hiv reservoir dynamics and the analysis of the prevalence of hcv resistance-associated mutations will help clinicians to improve the management of coinfected patients.

new markers of viral activity are now under investigation. besides hiv-rna and cd4 cells count, hiv-dna is an emerging marker of viral reservoir, that seems to be associated with the risk of hiv-related diseases, especially in hcv coinfected patients. new antiretroviral drugs, particularly integrase inhibitors, are expected to decrease residual viremia and, consequently, viral reservoir. monitoring of hiv-dna dynamics during antiretroviral treatment could lead to a better management of hiv infected population. also, the role of hcv in influencing hiv natural history requires careful monitoring. in particular, with a broader use of direct acting antiretroviral, the analysis of prevalence of hcv resistance associated mutation will be more and more important to manage patients with treatment failure.

Eligibility criteria:
inclusion criteria: * persons ≥ 18 years-old; * signing an informed consent to study participation and data treatment; * hiv-positive patients, beginning a new antiretroviral treatment patients or with clinically relevant events; * hcv-positive patients beginning an antiviral treatment with daa. exclusion criteria: * patient's deny * clinical contraindications to blood sample withdrawal

Keywords: hiv/hcv antiretroviral therapy hiv-dna direct acting antiviral
lipitor phase 4 clinical trial in hypercholesteremia patients with yellow coronary plaque

Conditions: Hypercholesteremia; Coronary Artery Disease

Summary: to evaluate the efficacy of intensive lipid-lowering therapy with lipitor on the changes of characteristics of yellow coronary plaque in subjects with hypercholesteremia accompanying coronary artery disease


Eligibility criteria:
inclusion criteria: * patients with hypercholesteremia * the indication of coronary angiography, coronary angioscopy and intravascular ultrasound are expected exclusion criteria: * patients who has current administration of lipitor or history of discontinued administration of lipitor * acute cardiac infarction

Keywords: lipitor atorvastatin hypercholesteremia yellow coronary plaque
attention and social behavior in children

Conditions: Anxiety

Summary: this study examines the way attention may be linked to temperamental risk for anxiety, social behavior and brain processes. the study aims to see if temperamentally at risk youth display an attention bias towards threat, and if anxiety symptoms can be reduced through attentional bias modification training.


Eligibility criteria:
inclusion criteria: * 9-12 year olds who do not meet exclusionary criteria (split into groups based on high and low temperamental shyness) exclusion criteria: * presence or permanent metal orthodontics or implanted metal devices * severe psychiatric diagnosis * iq under 70 as assessed by the wisc
bear bile pill as add-on the treatment of mdd

Conditions: Major Depressive Disorder

Summary: this is a single-center, double blind, randomized, placebo-controlled, parallel group study of bear bile pill, as add-on therapy in mdd patients conducted in shang hai mental health center. the purpose of this study is to determine the efficacy and safety of bear bile pill in reducing symptoms of depression in major depressive disorder (mdd)patients with inadequate response to current antidepressant therapy. following a screening period, subjects who meet the entry criteria will be randomized to treated with either placebo or 450mg bear bile pill three times daily for 8 weeks.


Eligibility criteria:
inclusion criteria: 1. meets the diagnostic and statistical manual of mental disorder, fifth edition, text revision (dsm-v) criteria for major depressive disorder (mdd); a single or recurrent episode without psychotic features ;codes are as follows: f32.0、f32.1、f32.2、f33.0、f33.1 、f33.2. 2. outpatients or inpatients. 3. male or female subjects aged 18-65 years. 4. patients have got standard treatment of ssri/snri monotherapy for more than 4 weeks in current episode of depression before trial entry. 5. madrs score greater than 20. 6. women of childbearing potential must be willing to use acceptable methods of contraception throughout the study period and the following one month. 7. the patient the patient fully understand and signed the informed consent form exclusion criteria: 1. patient has survived a suicide attempt or has acute suicidal tendencies (madrs item 10 \> 4). 2. comorbidity according to dsm-v, axis i except major depressive disorder. 3. failed 3 or more adequate antidepressant courses in current episode of depression. 4. madrs reduction ratio ≥25% within one week from the screening to the baseline visit. 5. depressive episode secondary to psychiatric illness or somatic disease. 6. serious and instable body disease such as cerebrovascular disease, liver and kidney disease, disease of internal secretion (abnormal thyroid function), blood disease; any history of seizures or other organic brain diseases. 7. history of alcohol or drug abuse over the last 6 months 8. allergic history to bear bile pills, or serious drug allergic history. 9. pregnant or lactating women and women of childbearing potential throughout the study period; men who have the desire of fertility within six months; 10. clinically significant changes in ecg or laboratory tests, including \>1.5x upper limit of normal liver function、over the limit of normal renal function and blood sugar、abnormal cardiac troponins、obvious abnormity in the thyroid function 11. treatment with mect or rtms in nearly three months. 12. treatment with a systematic psychological treatment in nearly three months.
study of the etx-4143 2.0 device in subjects with eye pain

Conditions: Eye Pain

Summary: a prospective early-feasibility study to evaluate the safety and effectiveness of the etx-4143 2.0 device. the device is intended to treat subjects with eye pain

a prospective early-feasibility study to evaluate the safety and effectiveness of the etx-4143 2.0 device. the device is intended to treat subjects who suffer from eye pain an do not get relieve from current medications or clinical treatments. thirty eyes will be enrolled and randomized 2:1 to the investigational treatment or a sham treatment. improvement in self-reported ocular pain and clinical safety measures will be evaluated. it is anticipated that the learnings from the study will be used to design future study of the etx-4143 2.0 device. all subjects will be followed for 8 weeks. subjects will only have the worse eye treated if both eyes meet the inclusion/exclusion criteria. a medical monitor will evaluate the safety of the study on a continual basis.

Eligibility criteria:
inclusion criteria: * documented history of eye pain with no relief from currently available medications or treatments * willing to forgo participation in any other clinical stud for the duration of this study * demonstrate sufficient cognitive awareness to comply with the examination process * willing and able to comply with the schedule for follow-up visits * willing to participate in the study as evidenced by signing an informed consent document exclusion criteria: * women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study time period, including the follow-up period * any active ocular infection or active ocular inflammation at the time of the screening visit * history of herpes keratitis, non-healing corneal epithelial defects, or neurotrophic keratopathy due to corneal herpetic disease, stem cell deficiency, diabetic keratopathy, severe lagophthalmos, or topical anesthetic abuse * any history of significant eye surgery with the prior 90 days * planned eye surgery during the entire study * participation in any clinical study of an investigational product within 30 days prior to enrollment * any history of serious, poorly controlled systemic or ophthalmic condition that could compromise the subject's ability to comply with the protocol or compromise their safety
characterization of a clinical subpopulation in children with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: this single-center, observational study is being conducted to identify a well-characterized subgroup within the asd patient population, based on clinical symptoms and biosample analysis.


Eligibility criteria:
inclusion criteria: * previously diagnosed with asd (based on dsm-5 criteria and supported by either adi-r or ados-2 scores) * at least two well documented head circumference values recorded within the first 2 years of life * participants must have a parent or reliable caregiver who agrees to provide information about the participant as required by the protocol and should be fluent in english exclusion criteria: * genetically identified asd (syndromic form of autism, e.g. fragile x) * episode of fever (i.e. ≥100.5 °f) or clinically significant illness without fever (as judged by the investigator), within 10 days before the study visit

Keywords: autism spectrum disorder endophenotyping observational
renal replacement therapy and in-hospital mortality incidence in cardiac surgery associated acute kidney injury

Conditions: Acute Kidney Injury

Summary: the goal of this study is to analyse the relation of severe acute kidney injury post cardiac surgery which characterised by the need of renal replacement therapy, with in-hospital postoperative mortality incidence. the main question it aims to answer: to compare between patients complicated with acute kidney injury and exposure of renal replacement therapy (aki-rrt) and patients complicated with acute kidney injury which does not require renal replacement therapy, in associated with in-hospital postoperative mortality.

type of study: observational study participant population: post cardiac surgery patients with condition of acute kidney injury postoperative, will be assigned into 2 groups, based on their exposure to renal replacement therapy. those groups are: group aki-rrt : patients with aki postoperative with exposure of renal replacement therapy group aki non rrt : patients with aki postoperative, with no exposure to renal replacement therapy researchers will compare group aki-rrt and aki non rrt to analyse the association to postoperative mortality, and other factors that related to mortality variable.

Eligibility criteria:
inclusion criteria: 1. patients who are at least 18 years old, underwent cardiac surgery in harapan kita national cardiovascular center from january 2020 to december 2022. 2. patients with condition was complicated with acute kidney injury (aki) which was characterised by an increase in serum creatinine \> 0.3 mg/dl or \> 150% of the preoperative serum creatinine value, which was checked within 12 hours post-operative. 3. all patients' data is recorded in the medical records unit. exclusion criteria: 1. patients with previous history of dialysis or renal failure in dialysis. 2. incomplete or loss of patients' data.

Keywords: acute kidney injury (aki) cardiac surgery renal replacement therapy mortality
effects of maternal smoking on fetal liver circulation

Conditions: Smoking, Cigarette; Maternal Exposure; Ultrasound; Fetal; Circulation; Liver

Summary: according to the hypothesis of this study presented, the effects of smoking on the fetus can be determined by the liver circulation and hepatic metabolism. the basic assumption of this project is; compensatory and pathological findings can be seen in the fetal liver circulation in babies of mothers who smoke and the findings can be valuable in predicting the direction of fetal development (growth retardation or normal development). in this study, the flow and shunt amounts in the fetal hepatic vessels in normal and smoking pregnant women will be calculated with the help of doppler us.

smoking is an agent that negatively affects of uteroplacental circulation and fetal development due to the chemical substances it contains, especially carbon monoxide and nicotine. according to the hypothesis of this study presented, the effects of smoking on the fetus can be determined by the liver circulation and hepatic metabolism. the basic assumption of this project is; compensatory and pathological findings can be seen in the fetal liver circulation in babies of mothers who smoke and the findings can be valuable in predicting the direction of fetal development (growth retardation or normal development). in this study, the flow and shunt amounts in the fetal hepatic vessels in normal and smoking pregnant women will be calculated with the help of doppler us.therefore, we try to delineate pathological circulatory pattern in these fetuses and shed light to the mechanism of smoking-induced abnormal fetal development. in addition, the effects of other maternal demographic factors, cigarette amount, cotinine and expiratory carbon monoxide levels (or any correlation between them) on hepatic circulation and fetal development will be examined.

Eligibility criteria:
inclusion criteria: * singleton pregnancy * smoking more than one cigarette in a day exclusion criteria: * fetal anomaly * pregnant women with systemic disease * younger than 18 years

Keywords: cotinine carbon monoxide smoking fetal liver circulation
effect of abdominal wall activity on the responses to meal ingestion

Conditions: Healthy

Summary: meal ingestion induces sensations that are influenced by a series of conditioning factors. aim: to determine the effect of abdominal wall activity on the responses to a standard probe meal. study in healthy subjects comparing postprandial digestive sensations (abdominal bloating and digestive well-being) during consecutive maneuvers of diaphragmatic contraction (i.e. descent) versus diaphragmatic relaxation (i.e. ascent) in a cross-over randomized design. primary outcome: effect of somatic maneuvers on abdominal bloating sensation; secondary aim: effect on digestive well-being. participants (16 women) will be instructed to eat a standard dinner the day before, to consume a standard breakfast at home after overnight fast, and to report to the laboratory, where the test meal will be administered 4 h after breakfast. studies will be conducted in a quiet, isolated room. participants will be taught to produce diaphragmatic contraction and visible abdominal distention. a probe meal up to maximal satiation will be administered to induce abdominal fullness/bloating sensation; immediately after ingestion, bloating sensation (from 0 to 10) and digestive well-being (from -5 to +5) will be scored during 8 alternating episodes (30 s each) in random sequence of diaphragmatic contraction (abdominal distension) versus diaphragmatic relaxation.


Eligibility criteria:
inclusion criteria: * non-obese exclusion criteria: * history of gastrointestinal symptoms * prior obesity * use of medications * history of anosmia and ageusia * current dieting * alcohol abuse * psychological disorders * eating disorders

Keywords: meal ingestion postprandial responses hedonic sensations homeostatic sensations abdominal wall activity abdominal distension
the optimal dosage of rocuronium for intraoperative neuromonitoring during thyroid surgery

Conditions: THYROIDECTOMY

Summary: the investigators tried to explore an alternative non-depolarizing muscle relaxant (rocuronium) and its optimal dosage to replace succinylcholine for ionm during thyroid surgery.time frame of outcome measure was during 30 to 70min after rocuronium injection. specific time points at which the will be assessed and for emg signals will be presented.

recurrent laryngeal nerve (rln) palsy is the most common and serious complication after thyroid surgery, and ranks among the leading reasons for medicolegal litigation of surgeons. intraoperative neuromonitoring (ionm) are being applied to prevent rln injury during thyroid surgery. ionm has been used as a means not only to localize and identify the rln, but also to predict cord function and elucidate the surgical pitfalls during preparation of rln. muscle relaxant is necessary for general anesthesia; it can facilitate tracheal intubation and stable conditions for surgery. however, the use of muscle relaxant might diminish the emg response during ionm and interfere with the interpretation of ionm results. eighty patients were randomized to receive one (group 1, n=40) or two (group 2, n=40) effective dose (ed95) of rocuronium to facilitate emg endotracheal tube insertion. evoked potentials were obtained per 5 minutes by stimulating vagus nerve from the time point of 30 to 70 minutes after administration of rocuronium. the magnitude of evoked potential at each time point and tracheal intubating condition were compared between groups. accelerometry \[twitch (% tw)\] was used to monitor the quantitative degree of neuromuscular transmission. the aim of this study was to explore an alternative non-depolarizing muscle relaxant (rocuronium) and its optimal dosage to replace succinylcholine for ionm. the ed95 of rocuronium is 0.3mg/kg and 2×ed95 is generally recommended as a standard intubation dosage.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of thyroid tumor exclusion criteria: * neuromuscular disease

Keywords: intra-operative neuromonitoring neuromuscular blocking agent rocuronium thyroid surgery
a study of ketamine in patients with treatment-resistant depression

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (trd).

this is a double-blind (patients and study personnel do not know the identity of the administered treatments), randomized (the drug is assigned by chance), placebo-controlled (placebo is a substance that appears identical to the treatment and has no active ingredients), parallel arm study (each group of patients will be treated at the same time). the study will consist of a screening phase of up to 4 weeks, a 4-week double-blind treatment phase (day 1 to day 29), and a 3-week post treatment (follow up) phase. in the double-blind phase, patients will receive over 4 weeks either intravenous (iv) infusions of placebo (2 or 3 times weekly) or iv infusions of ketamine (2 or 3 times weekly). the total study duration for each patient will be a maximum of 13 weeks.

Eligibility criteria:
inclusion criteria: * be medically stable on the basis of clinical laboratory tests performed at screening * meet diagnostic criteria for recurrent major depressive disorder (mdd), without psychotic features * have a history of inadequate response, ie treatment was not successful, to at least 1 antidepressant * have an inventory of depressive symptoms-clinician rated, 30 item (ids-c30) total score \>= 40 at screening and predose at day 1 * inpatient or agreed to be admitted to the clinic on each dosing day exclusion criteria: * has uncontrolled hypertension * has a history of, or current signs and symptoms of diseases, infections or conditions that in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments * has known allergies, hypersensitivity, or intolerance to ketamine or its excipients * is unable to read and understand the consent forms and patient reported outcomes, complete study-related procedures, and/or communicate with the study staff

Keywords: major depressive disorder treatment-resistant depression ketamine
cerebral metabolism in patients with refractory chronic cluster headache treated by occipital nerve stimulation

Conditions: Refractory Chronic Cluster Headache

Summary: the occipital nerve stimulation (ons) is used to treat patients with refractory primary chronic headache but its mechanism of action (moa) remains unknown. different hypothesis have been suggested in particular a specific action on cerebral generators involved in different types of primary headaches or a non specific action on pain modulatory network. the aim of this study, using the chronic cluster headache as a model, is to determine the changes in cerebral metabolism induced by ons to precise its moa in the treatment of primary chronic headache.


Eligibility criteria:
inclusion criteria: * age \> 18 years * chronic cluster headache (according to the ihs) * refractory in who a treatment by ons have been indicated * patient affiliated at social security, * informed consent signed exclusion criteria: * contraindication to mri * contraindication to 18f-fdg pet * women without contraception/pregnant/breast-feeding * patient non-compliant * patient on legal guardianship
safety and long-term effects of covid-19 vaccines in patients with pulmonary tumor

Conditions: Lung Cancer; Pulmonary Nodule, Solitary; Pulmonary Nodule, Multiple; COVID-19 Pneumonia; Vaccine Adverse Reaction; SARS-CoV-2 Acute Respiratory Disease

Summary: the objective of this study is to assess the inoculation-related symptoms and long-term effects of covid-19 vaccines in patients with lung cancer or pulmonary nodules in a real-world setting. the investigators aim to provide high-quality evidence for the covid-19 vaccines in cancer/pre-cancer patients, and to address their concern about the safety profile of the newly developed vaccines.

this study will enroll lung cancer/pulmonary nodule patients or healthy people who had undergone standard vaccination procedures against sars-cov-2/covid-19. this observatory study will apply an electronic questionnaire to collect general information and post-vaccination symptoms or adverse events of vaccinated pulmonary nodules/lung cancer patients and healthy control. the researchers will further analyze whether the vaccine will promote the progression of primary tumors/pulmonary nodules through long-term follow-up. the investigators aim to assess the adverse events and long-term impact of covid-19 vaccines in patients with lung cancer or pulmonary nodules in a real-world setting, to provide high-quality evidence for the covid-19 vaccines in cancer/pre-cancer patients, and to address their concern about the safety profile of the newly developed vaccines.

Eligibility criteria:
inclusion criteria: 1. pulmonary nodule/lung cancer patients confirmed by ct or pathological examination, who have been vaccinated against the sars-cov-2 2. pulmonary nodule/lung cancer patients confirmed by ct or pathological examination, who are not vaccinated against the sars-cov-2 3. healthy people who have been vaccinated against the sars-cov-2 exclusion criteria: 1. multiple malignancy in other parts of body; 2. infected with sars-cov-2 virus currently or in the past; 3. refuse to participate in this study.